Abstract |
To determine whether anti- tumor necrosis factors induce clinical response and remission in patients with Crohn's disease, PUBMED, OVID, and SCOPUS databases were searched for studies investigated the efficacy of anti- tumor necrosis factors on CD. Data were collected from 1966 to 2005 (up to 31 December). Types of outcome investigated were response (decrease in CDAI score >/=70 points) and remission (CDAI score </=150 points) 2 and 4 weeks after drug administration. The criteria for inclusion of studies in this analysis were exposure of patients with CD to any therapeutic dosage of any anti- tumor necrosis factors ( infliximab, cetrolizumab, CDP870, CDP571, etanercept, onarcept). The results showed that anti- tumor necrosis factors have improved only clinical response 2 weeks after administration of these drugs statistically, but their effects on clinical remission after 2 weeks and response and remission after 4 weeks have not been significant. It seems that anti- tumor necrosis factors are not effective for induction of response and remission in patients with Crohn's disease.
|
Authors | Roja Rahimi, Shekoufeh Nikfar, Mohammad Abdollahi |
Journal | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
(Biomed Pharmacother)
Vol. 61
Issue 1
Pg. 75-80
(Jan 2007)
ISSN: 0753-3322 [Print] France |
PMID | 17184965
(Publication Type: Journal Article, Meta-Analysis)
|
Chemical References |
- Antibodies, Monoclonal
- Gastrointestinal Agents
- Immunoglobulin G
- Receptors, Tumor Necrosis Factor
- Tumor Necrosis Factor-alpha
- Infliximab
- Etanercept
|
Topics |
- Acute Disease
- Antibodies, Monoclonal
(therapeutic use)
- Controlled Clinical Trials as Topic
- Crohn Disease
(drug therapy)
- Etanercept
- Gastrointestinal Agents
(therapeutic use)
- Humans
- Immunoglobulin G
(therapeutic use)
- Infliximab
- Receptors, Tumor Necrosis Factor
(therapeutic use)
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
|